Priovant - finding options to treat autoimmune diseases

Beyond Biotech - the podcast from Labiotech

Indhold leveret af Labiotech. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Labiotech eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

6M ago 30:05

MP3•Episode hjem

US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options.

The company's lead asset, brepocitinib, is a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL6, IL12, and IL23—with a single, targeted therapy.

Brepocitinib has generated positive data in seven phase 2 studies with oral once-daily administration. It is currently being evaluated in a phase 3 program for dermatomyositis and is entering a phase 3 program for non-infectious uveitis.

This week on the podcast we have a conversation with Priovant’s CEO Benjamin Zimmer about dermatomyositis, non-infectious uveitis, current treatments, potential options, and how brepocitinib is making a difference.

00:55-02:34: About Priovant
02:34-06:38: What are dermatomyositis and non-infectious uveitis?
06:38-08:35: What are the current treatments?
08:35-12:32: What is brepocitinib?
12:32-15:36: Are there other treatments in development?
15:36-17:50: What is your relationship with Pfizer?
17:50-20:48: Brepocitinib clinical trials
20:48-24:06: Future plans and timeline
24:06-27:59: Finding patients for clinical trials
27:59-29:19: Future opportunities
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Kapitler

1. Priovant - finding options to treat autoimmune diseases (00:00:00)

2. About Priovant  (00:00:55)

3. What are dermatomyositis and non-infectious uveitis?  (00:02:34)

4. What are the current treatments?  (00:06:38)

5. What is brepocitinib?  (00:08:35)

6. Are there other treatments in development?  (00:12:32)

7. What is your relationship with Pfizer?  (00:15:36)

8. Brepocitinib clinical trials  (00:17:50)

9. Future plans and timeline  (00:20:48)

10. Finding patients for clinical trials  (00:24:06)

11. Future opportunities (00:27:59)

129 episoder

#News #Tech News #Labiotech